Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK; Joint first authors.
Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK; Joint first authors.
Trends Biotechnol. 2017 Nov;35(11):1062-1073. doi: 10.1016/j.tibtech.2017.07.004. Epub 2017 Aug 1.
Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.
与年龄相关的疾病是导致死亡和医疗成本的主要原因。降低衰老速度将带来巨大的医疗和经济效益。众多基因和途径被认为可以调节模型生物的衰老，这催生了一批新的抗衰老公司。这些方法包括从药物发现到大数据方法和直接面向消费者（DTC）策略的各种途径。商业化面临的挑战和陷阱包括依赖于短期模型生物的发现，对衰老的生物学理解不足，以及在进行衰老临床试验方面的障碍。有大量潜在的与衰老相关的干预措施和靶点，但由于验证时间长，只有一小部分可以探索用于临床应用。然而，如果有一家公司成功，其影响将是巨大的。
